Orano Med, a subsidiary of the Orano group with a focus on nuclear medicine, announced on Thursday that its collaboration with Swiss biotechnology company Roche (SIX: RO, ROG; OTCQX: RHHBY) is entering the next phase, moving pretargeted radioimmunotherapy (PRIT) into clinical development.
The technology pretargets tumours with an antibody that captures chelated lead-212 (212Pb) to selectively target cancer cells, with Orano Med responsible for 212Pb manufacturing in France and the United States.
The collaboration focuses on developing a therapeutic solution targeting the carcinoembryonic antigen (CEA), overexpressed in colorectal, pancreatic, gastric, and certain lung cancers. CEA is minimally expressed in normal tissues, making it a suitable target for antibody-based therapies and radioimmunotherapy.
Roche will sponsor a phase 1 clinical trial expected to start in the first half of 2026, marking the first human studies for this PRIT approach.
The initiative represents a broader platform for alpha radioimmunotherapies, reinforcing Orano Med's leading position in targeted alpha therapy development.
The companies' combined expertise in nuclear medicine and oncology aims to address cancers with limited current treatment options.
Ascletis announces submission of US IND application for oral obesity combination therapy
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Medivir secures US patent protection for fostrox and lenvatinib combination until 2044
PharmaLogic to acquire CDMO business and manufacturing facility from Lantheus
Ribo submits European Clinical Trial Application for SR122 in mixed and severe dyslipidaemia
Spermosens and Genea agree IVF study of JUNO-Checked in Australia
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
Charles River Laboratories to acquire Frontage bioanalysis and DMPK businesses for USD470m
UCB and Biogen report additional positive Phase 3 data for investigational lupus treatment